The humanized monoclonal antibody trastuzumab was the first targeted therapy for the HER2 protein, targeting its extracellular domain; as an advanced and adjuvant treatment with chemotherapy for patients with HER2+ BC, trastuzumab has been associated with a significant survival benefit [5]. This evidence concerns the gene ERBB2 and breast cancer.